Volume 15, Issue 35, January - June, 2021

A novel and Emerging Coronavirus Infection: Repurposing and Scale of Advances of Therapeutics, Imunotherapeutics and Vaccine Development

Tapas Kumar Mohapatra¹, Reena Rani Nayak², Arijit Mondal³, Sitansu Sekhar Nanda^4♦

¹Associate professor, HOD, Department of pharmacology, IMT Pharmacy College, Gopalpur, Puri, 752004, India
²Odisha drugs and Chemicals ltd, Mancheswar Industrial estate, Bhubaneswar, Odisha, India
³Department of pharmaceutical chemistry, Bengal college of pharmaceutical Technology, Dubrajpur 731 123, West Bengal, India
⁴Department of Chemistry, Myongji University, Yongin, 03674, South Korea; E-mail: nandasitansusekhar@gmail.com

^♦Corresponding author
Department of Chemistry, Myongji University, Yongin, 03674, South Korea; E-mail: nandasitansusekhar@gmail.com

ABSTRACT

A new coronavirus (nCOVID-19) has appeared in China for the first time, inducing various effects in humans and strongly linked to those induced by SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). Several cases of this infection with the coronavirus respiratory syndrome have also been identified in over 215 countries. More than 16,482,747 cases of coronavirus disease 2019 have been recorded since December 2019 and about 653,325 deaths around the world have occurred. In the USA, Brazil, India, Russia, South Africa, Mexico, Peru, Chile, Spain, United Kingdom, Italy, Germany and France, most cases have been registered. This public health epidemic has been the emergence of this emerging illness which threatens to propagate exponentially across the globe. The accepted cases are subdivided into four groups dependent on clinical evidence, which involve mild, moderate, serious and critical instances. Of the active cases, approximately 1% were seriously/critically ill and 99% were in mild conditions. The infection fatality incidence was roughly 6%. This analysis focuses on knowledge currently available about COVID-19's etiology, clinical signs, diagnosis, and mode of action. In addition, according to current evidence, we provide a summary of the diagnosis methods and treatment for this condition. This review information will help the physician identify and manage COVID-19 effectively.

Keywords: nCOVID-19; Vaccine; Therapeutics

Drug Discovery, 2021, 15(35), 23-50

PDF